Use of chemotherapy in patients with oesophageal, stomach, colon, rectal, liver, pancreatic, lung, and ovarian cancer: an International Cancer Benchmarking Partnership (ICBP) population-based study
Background There are few data on international variation in chemotherapy use, despite it being a key treatment type for some patients with cancer. Here, we aimed to examine the presence and size of such variation. Methods This population-based study used data from Norway, the four UK nations (Englan...
Published in: | The Lancet Oncology |
---|---|
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
Format: | Article in Journal/Newspaper |
Language: | English |
Published: |
2024
|
Subjects: | |
Online Access: | https://pure.qub.ac.uk/en/publications/b8b3c5b4-4579-4ff9-9fe7-be07b118bfbe https://doi.org/10.1016/S1470-2045(24)00031-7 https://pureadmin.qub.ac.uk/ws/files/595003435/1-s2.0-S1470204524000317-main.pdf |
id |
ftqueensubelpubl:oai:pure.qub.ac.uk/portal:publications/b8b3c5b4-4579-4ff9-9fe7-be07b118bfbe |
---|---|
record_format |
openpolar |
institution |
Open Polar |
collection |
Queen's University Belfast Research Portal |
op_collection_id |
ftqueensubelpubl |
language |
English |
topic |
Victoria Lung Rectal Neoplasms Ontario - epidemiology Benchmarking State Medicine Humans Stomach Liver Ovarian Neoplasms - drug therapy - epidemiology Aged 80 and over Middle Aged Adolescent Colonic Neoplasms - drug therapy - epidemiology Male Female Adult Young Adult /dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being name=SDG 3 - Good Health and Well-being |
spellingShingle |
Victoria Lung Rectal Neoplasms Ontario - epidemiology Benchmarking State Medicine Humans Stomach Liver Ovarian Neoplasms - drug therapy - epidemiology Aged 80 and over Middle Aged Adolescent Colonic Neoplasms - drug therapy - epidemiology Male Female Adult Young Adult /dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being name=SDG 3 - Good Health and Well-being McPhail, Sean Barclay, Matthew E. Johnson, Shane A. Swann, Ruth Alvi, Riaz Barisic, Andriana Bucher, Oliver Creighton, Nicola Denny, Cheryl A. Dewar, Ron A. Donnelly, David W. Dowden, Jeff J. Downie, Laura Finn, Norah Gavin, Anna T. Habbous, Steven Huws, Dyfed W. May, Leon McClure, Carol A. Møller, Bjørn Musto, Grace Nilssen, Yngvar Saint-Jacques, Nathalie Sarker, Sabuj Shack, Lorraine Tian, Xiaoyi Thomas, Robert J. S. Thomson, Catherine S. Wang, Haiyan Woods, Ryan R. You, Hui Lyratzopoulos, Georgios Bennett, Damien Use of chemotherapy in patients with oesophageal, stomach, colon, rectal, liver, pancreatic, lung, and ovarian cancer: an International Cancer Benchmarking Partnership (ICBP) population-based study |
topic_facet |
Victoria Lung Rectal Neoplasms Ontario - epidemiology Benchmarking State Medicine Humans Stomach Liver Ovarian Neoplasms - drug therapy - epidemiology Aged 80 and over Middle Aged Adolescent Colonic Neoplasms - drug therapy - epidemiology Male Female Adult Young Adult /dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being name=SDG 3 - Good Health and Well-being |
description |
Background There are few data on international variation in chemotherapy use, despite it being a key treatment type for some patients with cancer. Here, we aimed to examine the presence and size of such variation. Methods This population-based study used data from Norway, the four UK nations (England, Northern Ireland, Scotland, and Wales), eight Canadian provinces (Alberta, British Columbia, Manitoba, Newfoundland and Labrador, Nova Scotia, Ontario, Prince Edward Island, and Saskatchewan), and two Australian states (New South Wales and Victoria). Patients aged 15–99 years diagnosed with cancer in eight different sites (oesophageal, stomach, colon, rectal, liver, pancreatic, lung, or ovarian cancer), with no other primary cancer diagnosis occurring from within the 5 years before to 1 year after the index cancer diagnosis or during the study period were included in the study. We examined variation in chemotherapy use from 31 days before to 365 days after diagnosis and time to its initiation, alongside related variation in patient group differences. Information was obtained from cancer registry records linked to clinical or patient management system data or hospital administration data. Random-effects meta-analyses quantified interjurisdictional variation using 95% prediction intervals (95% PIs). Findings Between Jan 1, 2012, and Dec 31, 2017, of 893 461 patients with a new diagnosis of one of the studied cancers, 111 569 (12·5%) did not meet the inclusion criteria, and 781 892 were included in the analysis. There was large interjurisdictional variation in chemotherapy use for all studied cancers, with wide 95% PIs: 47·5 to 81·2 (pooled estimate 66·4%) for ovarian cancer, 34·9 to 59·8 (47·2%) for oesophageal cancer, 22·3 to 62·3 (40·8%) for rectal cancer, 25·7 to 55·5 (39·6%) for stomach cancer, 17·2 to 56·3 (34·1%) for pancreatic cancer, 17·9 to 49·0 (31·4%) for lung cancer, 18·6 to 43·8 (29·7%) for colon cancer, and 3·5 to 50·7 (16·1%) for liver cancer. For patients with stage 3 colon cancer, the ... |
format |
Article in Journal/Newspaper |
author |
McPhail, Sean Barclay, Matthew E. Johnson, Shane A. Swann, Ruth Alvi, Riaz Barisic, Andriana Bucher, Oliver Creighton, Nicola Denny, Cheryl A. Dewar, Ron A. Donnelly, David W. Dowden, Jeff J. Downie, Laura Finn, Norah Gavin, Anna T. Habbous, Steven Huws, Dyfed W. May, Leon McClure, Carol A. Møller, Bjørn Musto, Grace Nilssen, Yngvar Saint-Jacques, Nathalie Sarker, Sabuj Shack, Lorraine Tian, Xiaoyi Thomas, Robert J. S. Thomson, Catherine S. Wang, Haiyan Woods, Ryan R. You, Hui Lyratzopoulos, Georgios Bennett, Damien |
author_facet |
McPhail, Sean Barclay, Matthew E. Johnson, Shane A. Swann, Ruth Alvi, Riaz Barisic, Andriana Bucher, Oliver Creighton, Nicola Denny, Cheryl A. Dewar, Ron A. Donnelly, David W. Dowden, Jeff J. Downie, Laura Finn, Norah Gavin, Anna T. Habbous, Steven Huws, Dyfed W. May, Leon McClure, Carol A. Møller, Bjørn Musto, Grace Nilssen, Yngvar Saint-Jacques, Nathalie Sarker, Sabuj Shack, Lorraine Tian, Xiaoyi Thomas, Robert J. S. Thomson, Catherine S. Wang, Haiyan Woods, Ryan R. You, Hui Lyratzopoulos, Georgios Bennett, Damien |
author_sort |
McPhail, Sean |
title |
Use of chemotherapy in patients with oesophageal, stomach, colon, rectal, liver, pancreatic, lung, and ovarian cancer: an International Cancer Benchmarking Partnership (ICBP) population-based study |
title_short |
Use of chemotherapy in patients with oesophageal, stomach, colon, rectal, liver, pancreatic, lung, and ovarian cancer: an International Cancer Benchmarking Partnership (ICBP) population-based study |
title_full |
Use of chemotherapy in patients with oesophageal, stomach, colon, rectal, liver, pancreatic, lung, and ovarian cancer: an International Cancer Benchmarking Partnership (ICBP) population-based study |
title_fullStr |
Use of chemotherapy in patients with oesophageal, stomach, colon, rectal, liver, pancreatic, lung, and ovarian cancer: an International Cancer Benchmarking Partnership (ICBP) population-based study |
title_full_unstemmed |
Use of chemotherapy in patients with oesophageal, stomach, colon, rectal, liver, pancreatic, lung, and ovarian cancer: an International Cancer Benchmarking Partnership (ICBP) population-based study |
title_sort |
use of chemotherapy in patients with oesophageal, stomach, colon, rectal, liver, pancreatic, lung, and ovarian cancer: an international cancer benchmarking partnership (icbp) population-based study |
publishDate |
2024 |
url |
https://pure.qub.ac.uk/en/publications/b8b3c5b4-4579-4ff9-9fe7-be07b118bfbe https://doi.org/10.1016/S1470-2045(24)00031-7 https://pureadmin.qub.ac.uk/ws/files/595003435/1-s2.0-S1470204524000317-main.pdf |
geographic |
Newfoundland Norway |
geographic_facet |
Newfoundland Norway |
genre |
Newfoundland Prince Edward Island |
genre_facet |
Newfoundland Prince Edward Island |
op_source |
McPhail , S , Barclay , M E , Johnson , S A , Swann , R , Alvi , R , Barisic , A , Bucher , O , Creighton , N , Denny , C A , Dewar , R A , Donnelly , D W , Dowden , J J , Downie , L , Finn , N , Gavin , A T , Habbous , S , Huws , D W , May , L , McClure , C A , Møller , B , Musto , G , Nilssen , Y , Saint-Jacques , N , Sarker , S , Shack , L , Tian , X , Thomas , R J S , Thomson , C S , Wang , H , Woods , R R , You , H , Lyratzopoulos , G , ICBP Module 9 Chemotherapy Group & Bennett , D 2024 , ' Use of chemotherapy in patients with oesophageal, stomach, colon, rectal, liver, pancreatic, lung, and ovarian cancer: an International Cancer Benchmarking Partnership (ICBP) population-based study ' , Lancet Oncology , vol. 25 , no. 3 , pp. 338-351 . https://doi.org/10.1016/S1470-2045(24)00031-7 |
op_relation |
https://pure.qub.ac.uk/en/publications/b8b3c5b4-4579-4ff9-9fe7-be07b118bfbe |
op_rights |
info:eu-repo/semantics/openAccess |
op_doi |
https://doi.org/10.1016/S1470-2045(24)00031-7 |
container_title |
The Lancet Oncology |
container_volume |
25 |
container_issue |
3 |
container_start_page |
338 |
op_container_end_page |
351 |
_version_ |
1809923434666262528 |
spelling |
ftqueensubelpubl:oai:pure.qub.ac.uk/portal:publications/b8b3c5b4-4579-4ff9-9fe7-be07b118bfbe 2024-09-09T19:53:59+00:00 Use of chemotherapy in patients with oesophageal, stomach, colon, rectal, liver, pancreatic, lung, and ovarian cancer: an International Cancer Benchmarking Partnership (ICBP) population-based study McPhail, Sean Barclay, Matthew E. Johnson, Shane A. Swann, Ruth Alvi, Riaz Barisic, Andriana Bucher, Oliver Creighton, Nicola Denny, Cheryl A. Dewar, Ron A. Donnelly, David W. Dowden, Jeff J. Downie, Laura Finn, Norah Gavin, Anna T. Habbous, Steven Huws, Dyfed W. May, Leon McClure, Carol A. Møller, Bjørn Musto, Grace Nilssen, Yngvar Saint-Jacques, Nathalie Sarker, Sabuj Shack, Lorraine Tian, Xiaoyi Thomas, Robert J. S. Thomson, Catherine S. Wang, Haiyan Woods, Ryan R. You, Hui Lyratzopoulos, Georgios Bennett, Damien 2024-03 application/pdf https://pure.qub.ac.uk/en/publications/b8b3c5b4-4579-4ff9-9fe7-be07b118bfbe https://doi.org/10.1016/S1470-2045(24)00031-7 https://pureadmin.qub.ac.uk/ws/files/595003435/1-s2.0-S1470204524000317-main.pdf eng eng https://pure.qub.ac.uk/en/publications/b8b3c5b4-4579-4ff9-9fe7-be07b118bfbe info:eu-repo/semantics/openAccess McPhail , S , Barclay , M E , Johnson , S A , Swann , R , Alvi , R , Barisic , A , Bucher , O , Creighton , N , Denny , C A , Dewar , R A , Donnelly , D W , Dowden , J J , Downie , L , Finn , N , Gavin , A T , Habbous , S , Huws , D W , May , L , McClure , C A , Møller , B , Musto , G , Nilssen , Y , Saint-Jacques , N , Sarker , S , Shack , L , Tian , X , Thomas , R J S , Thomson , C S , Wang , H , Woods , R R , You , H , Lyratzopoulos , G , ICBP Module 9 Chemotherapy Group & Bennett , D 2024 , ' Use of chemotherapy in patients with oesophageal, stomach, colon, rectal, liver, pancreatic, lung, and ovarian cancer: an International Cancer Benchmarking Partnership (ICBP) population-based study ' , Lancet Oncology , vol. 25 , no. 3 , pp. 338-351 . https://doi.org/10.1016/S1470-2045(24)00031-7 Victoria Lung Rectal Neoplasms Ontario - epidemiology Benchmarking State Medicine Humans Stomach Liver Ovarian Neoplasms - drug therapy - epidemiology Aged 80 and over Middle Aged Adolescent Colonic Neoplasms - drug therapy - epidemiology Male Female Adult Young Adult /dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being name=SDG 3 - Good Health and Well-being article 2024 ftqueensubelpubl https://doi.org/10.1016/S1470-2045(24)00031-7 2024-07-15T23:49:25Z Background There are few data on international variation in chemotherapy use, despite it being a key treatment type for some patients with cancer. Here, we aimed to examine the presence and size of such variation. Methods This population-based study used data from Norway, the four UK nations (England, Northern Ireland, Scotland, and Wales), eight Canadian provinces (Alberta, British Columbia, Manitoba, Newfoundland and Labrador, Nova Scotia, Ontario, Prince Edward Island, and Saskatchewan), and two Australian states (New South Wales and Victoria). Patients aged 15–99 years diagnosed with cancer in eight different sites (oesophageal, stomach, colon, rectal, liver, pancreatic, lung, or ovarian cancer), with no other primary cancer diagnosis occurring from within the 5 years before to 1 year after the index cancer diagnosis or during the study period were included in the study. We examined variation in chemotherapy use from 31 days before to 365 days after diagnosis and time to its initiation, alongside related variation in patient group differences. Information was obtained from cancer registry records linked to clinical or patient management system data or hospital administration data. Random-effects meta-analyses quantified interjurisdictional variation using 95% prediction intervals (95% PIs). Findings Between Jan 1, 2012, and Dec 31, 2017, of 893 461 patients with a new diagnosis of one of the studied cancers, 111 569 (12·5%) did not meet the inclusion criteria, and 781 892 were included in the analysis. There was large interjurisdictional variation in chemotherapy use for all studied cancers, with wide 95% PIs: 47·5 to 81·2 (pooled estimate 66·4%) for ovarian cancer, 34·9 to 59·8 (47·2%) for oesophageal cancer, 22·3 to 62·3 (40·8%) for rectal cancer, 25·7 to 55·5 (39·6%) for stomach cancer, 17·2 to 56·3 (34·1%) for pancreatic cancer, 17·9 to 49·0 (31·4%) for lung cancer, 18·6 to 43·8 (29·7%) for colon cancer, and 3·5 to 50·7 (16·1%) for liver cancer. For patients with stage 3 colon cancer, the ... Article in Journal/Newspaper Newfoundland Prince Edward Island Queen's University Belfast Research Portal Newfoundland Norway The Lancet Oncology 25 3 338 351 |